{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:08:55Z","timestamp":1791227335671,"version":"4.1.0"},"reference-count":88,"publisher":"BMJ","issue":"11","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Gut"],"accepted":{"date-parts":[[2015,9,3]]},"published-print":{"date-parts":[[2015,11]]},"abstract":"<jats:p>Chronic HCV infections represent a major worldwide public health problem and are responsible for a large proportion of liver related deaths, mostly because of HCV-associated hepatocellular carcinoma and cirrhosis. The treatment of HCV has undergone a rapid and spectacular revolution. In the past 5\u2005years, the launch of direct acting antiviral drugs has seen sustained virological response rates reach 90% and above for many patient groups. The new treatments are effective, well tolerated, allow for shorter treatment regimens and offer new opportunities for previously excluded groups. This therapeutic revolution has changed the rules for treatment of HCV, moving the field towards an interferon-free era and raising the prospect of HCV eradication. This manuscript addresses the new challenges regarding treatment optimisation in the real world, improvement of antiviral efficacy in \u2018hard-to-treat\u2019 groups, the management of patients whose direct acting antiviral drug treatment was unsuccessful, and access to diagnosis and treatment in different parts of the world.<\/jats:p>","DOI":"10.1136\/gutjnl-2015-310421","type":"journal-article","created":{"date-parts":[[2015,10,8]],"date-time":"2015-10-08T07:23:23Z","timestamp":1444289003000},"page":"1824-1833","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":125,"title":["Hepatitis C virus treatment in the real world: optimising treatment and access to therapies"],"prefix":"10.1136","volume":"64","author":[{"given":"Fabien","family":"Zoulim","sequence":"first","affiliation":[{"name":"Universit\u00e9 Lyon 1, Cancer Research Center of Lyon (CRCL), INSERM U1052, Hospices Civils de Lyon, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T Jake","family":"Liang","sequence":"additional","affiliation":[{"name":"Liver Diseases Branch, NIDDK, NIH, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander L","family":"Gerbes","sequence":"additional","affiliation":[{"name":"Klinikum der LMU M\u00fcnchen-Grosshadern, Liver Center Munich, University Hospital Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Aghemo","sequence":"additional","affiliation":[{"name":"U O Gastroenterologia ed Epatologia, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Deuffic-Burban","sequence":"additional","affiliation":[{"name":"Inserm, IAME, UMR 1137, Paris, France"},{"name":"Univ Paris Diderot, Sorbonne Paris Cit\u00e9, Paris, France"},{"name":"Inserm, LIRIC-UMR995, Lille, France"},{"name":"Univ Lille, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey","family":"Dusheiko","sequence":"additional","affiliation":[{"name":"UCL Institute of Liver and Digestive Health, Royal Free Hospital London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W","family":"Fried","sequence":"additional","affiliation":[{"name":"UNC Liver Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanislas","family":"Pol","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Descartes, INSERM USM20, Institut Pasteur et Assistance Publique\u2013 H\u00f4pitaux de Paris, D\u00e9partement d'H\u00e9patologie, H\u00f4pital Cochin, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen Kurt","family":"Rockstroh","sequence":"additional","affiliation":[{"name":"Department of Medicine I, J\u00fcrgen Kurt Rockstroh: University Hospital Bonn, Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norah A","family":"Terrault","sequence":"additional","affiliation":[{"name":"University of California San Francisco, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Wiktor","sequence":"additional","affiliation":[{"name":"World Health Organization, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2015,10,8]]},"reference":[{"key":"2025090800171591000_64.11.1824.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60844-8"},{"key":"2025090800171591000_64.11.1824.2","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2012-302122"},{"key":"2025090800171591000_64.11.1824.3","doi-asserted-by":"publisher","DOI":"10.1126\/science.1257737"},{"key":"2025090800171591000_64.11.1824.4","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2012-302144"},{"key":"2025090800171591000_64.11.1824.5","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.12627"},{"key":"2025090800171591000_64.11.1824.6","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.144878"},{"key":"2025090800171591000_64.11.1824.7","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ396"},{"key":"2025090800171591000_64.11.1824.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.06.025"},{"key":"2025090800171591000_64.11.1824.9","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2014-308163"},{"key":"2025090800171591000_64.11.1824.10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0055285"},{"key":"2025090800171591000_64.11.1824.11","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2014-307498"},{"key":"2025090800171591000_64.11.1824.12","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(13)70033-1"},{"key":"2025090800171591000_64.11.1824.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.12.031"},{"key":"2025090800171591000_64.11.1824.14","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(14)71002-3"},{"key":"2025090800171591000_64.11.1824.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402454"},{"key":"2025090800171591000_64.11.1824.16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306227"},{"key":"2025090800171591000_64.11.1824.17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402355"},{"key":"2025090800171591000_64.11.1824.18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1316366"},{"key":"2025090800171591000_64.11.1824.19","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)70050-2"},{"key":"2025090800171591000_64.11.1824.20","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.05.010"},{"key":"2025090800171591000_64.11.1824.21","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.04.045"},{"key":"2025090800171591000_64.11.1824.22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1315722"},{"key":"2025090800171591000_64.11.1824.23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1408921"},{"key":"2025090800171591000_64.11.1824.24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1401561"},{"key":"2025090800171591000_64.11.1824.25","unstructured":"Feld , et al . International Symposium on Viral Hepatitis and Liver Diseases. 2015."},{"key":"2025090800171591000_64.11.1824.26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402869"},{"key":"2025090800171591000_64.11.1824.27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1208953"},{"key":"2025090800171591000_64.11.1824.28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1214854"},{"key":"2025090800171591000_64.11.1824.29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1214853"},{"key":"2025090800171591000_64.11.1824.30","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12312"},{"key":"2025090800171591000_64.11.1824.31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1316145"},{"key":"2025090800171591000_64.11.1824.32","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60159-3"},{"key":"2025090800171591000_64.11.1824.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.04.023"},{"issue":"(Suppl)","key":"2025090800171591000_64.11.1824.34","first-page":"LP28","article-title":"Efficacy of oral sofosbuvir-based combinations in HCV genotype 4 monoinfected patients from the French observational cohort ANRS C022 HEPATHER","volume":"62","author":"Fontaine","year":"2015","journal-title":"J Hepatol"},{"key":"2025090800171591000_64.11.1824.35","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)00157-7"},{"key":"2025090800171591000_64.11.1824.36","doi-asserted-by":"crossref","unstructured":"Gane EJ , Hyland RH , An D , et al . Efficacy of Ledipasvir and Sofosbuvir, With or Without Ribavirin, for 12 Weeks in Patients With HCV Genotype 3 or 6 Infection. Gastroenterology Published Online First: 7 Aug 2015. doi:10.1053\/j.gastro.2015.07.063 doi:10.1053\/j.gastro.2015.07.063","DOI":"10.1053\/j.gastro.2015.07.063"},{"key":"2025090800171591000_64.11.1824.37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.03.025"},{"key":"2025090800171591000_64.11.1824.38","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27950"},{"issue":"(Suppl 1)","key":"2025090800171591000_64.11.1824.39","first-page":"219A","article-title":"Safety and efficacy of sofosbuvir-containing regimens for hepatitis C: real-world experience in a diverse, longitudinal observational cohort","volume":"60","author":"Jensen","year":"2014","journal-title":"Hepatology"},{"key":"2025090800171591000_64.11.1824.40","doi-asserted-by":"crossref","unstructured":"Renet S , Chaumais MC , Antonini T , et al , Extreme Bradycardia After First Doses of Sofosbuvir and Daclatasvir in Patients Receiving Amiodarone: 2 Cases Including a Rechallenge. Gastroenterology 2015. in press.","DOI":"10.1053\/j.gastro.2015.07.051"},{"key":"2025090800171591000_64.11.1824.41","unstructured":"Sulkowski MS , Vargas HE , Di Bisceglie AM , et al ., for the HCV-TARGET Study Group. Simeprevir plus Sofosbuvir with or without ribavirin for the treatment of patients with HCV genotype 1 infection in real-world clinical practice: the HCV TARGET Study. Hepatology 2014:60 (suppl 1):955 (abstract)."},{"key":"2025090800171591000_64.11.1824.42","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2015.218"},{"key":"2025090800171591000_64.11.1824.43","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(15)30149-5"},{"issue":"(Suppl 2)","key":"2025090800171591000_64.11.1824.44","doi-asserted-by":"crossref","first-page":"S652","DOI":"10.1016\/S0168-8278(15)31042-4","article-title":"Safety and effectiveness of sofosbuvir-based regimens for the treatment of hepatitis C genotype 3 & 4 infections: interim analysis of a prospective, observational study","volume":"62","author":"Alqahtani","year":"2015","journal-title":"J Hepatol"},{"key":"2025090800171591000_64.11.1824.45","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13300"},{"key":"2025090800171591000_64.11.1824.46","unstructured":"Gane EJ , Hyland RH , An D , et al . High Efficacy of LDV\/SOF Regimens for 12 Weeks for Patients with HCV Genotype 3 or 6 Infection. Hepatology 2014;60:1274A\u20135A."},{"key":"2025090800171591000_64.11.1824.47","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27726"},{"key":"2025090800171591000_64.11.1824.48","doi-asserted-by":"crossref","unstructured":"Welzel T , Cornberg M , Petersen J , et al . Daclatasvir plus sofosbuvir with or without ribavirin in patients with chronic HCV infection: interim analysis of a multicenter compassionate use program. J Viral Hepatitis 2015;(Suppl 2):24\u201325.","DOI":"10.1111\/jvh.12333_6"},{"key":"2025090800171591000_64.11.1824.49","doi-asserted-by":"crossref","unstructured":"Hezode C , de Ledinghen V , Fontaine H , et al . Daclatasvir plus sofosbuvir with or without ribavirin in patients with HCV genotype 3: interim analysis of a compassionate use program. J Hepatol 2015;62 (Suppl 2): LP05.","DOI":"10.1016\/S0168-8278(15)30159-8"},{"key":"2025090800171591000_64.11.1824.50","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2012-303852"},{"key":"2025090800171591000_64.11.1824.51","doi-asserted-by":"crossref","unstructured":"Testoni B , Durantel D , Lebosse F , et al . Ribavirin restores IFNalpha responsiveness in HCV-infected livers by epigenetic remodelling at interferon stimulated genes. Gut Published Online First: 16 Jun 2015. doi:10.1136\/gutjnl-2014-309011 doi:10.1136\/gutjnl-2014-309011","DOI":"10.1136\/gutjnl-2014-309011"},{"key":"2025090800171591000_64.11.1824.52","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501315"},{"key":"2025090800171591000_64.11.1824.53","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503153"},{"key":"2025090800171591000_64.11.1824.54","unstructured":"Hill AM , Simmons B , Saleem J , et al . Five-year risk of late relapse or reinfection with hepatitis C after sustained virological response: meta-analysis of 49 studies in 8534 patients. CROI 2015. February 23\u201326, 2015. Seattle, Washington. Abstract 654."},{"issue":"(Suppl 2)","key":"2025090800171591000_64.11.1824.55","doi-asserted-by":"crossref","first-page":"S257","DOI":"10.1016\/S0168-8278(15)30147-1","article-title":"Safety of Ombitasvir\/Paritaprevir\/ritonavir plus Dasabuvir for treating HCV GT1 infection in patients with severe renal impairment or end-stage renal disease: the RUBY-1 study","volume":"62","author":"Pockros","year":"2015","journal-title":"J Hepatol"},{"issue":"(Suppl 2)","key":"2025090800171591000_64.11.1824.56","first-page":"S264","article-title":"LP02: C-surfer: grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease","volume":"62","author":"Roth","year":"2015","journal-title":"J Hepatol"},{"key":"2025090800171591000_64.11.1824.57","unstructured":"Carrier P , Jaccard A , Jacques J , et al . HCV-associated B-cell non-Hodgkin lymphomas and new direct antiviral agents. Liver Int Published Online First: 22 Jun 2015."},{"key":"2025090800171591000_64.11.1824.58","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27623"},{"key":"2025090800171591000_64.11.1824.59","doi-asserted-by":"publisher","DOI":"10.1016\/j.gcb.2008.07.004"},{"key":"2025090800171591000_64.11.1824.60","unstructured":"Petersen T GL , Townsend K , Calderon M , et al . Pill burden & treatment length reduce adherence to IFN-free hepatitis C therapy in an urban cohort. 21st Conference on Retroviruses and Opportunistic Infections; 3\u20136 March 2014:Abstract 667."},{"key":"2025090800171591000_64.11.1824.61","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2007.05.025"},{"issue":"(Suppl 2)","key":"2025090800171591000_64.11.1824.62","doi-asserted-by":"crossref","first-page":"S190","DOI":"10.1016\/S0168-8278(15)30009-X","article-title":"O002: treatment of decompensated HCV cirrhosis in patients with diverse genotypes: 12 weeks sofosbuvir and NS5A inhibitors with\/without ribavirin is effective in HCV genotypes 1 and 3","volume":"62","author":"Foster","year":"2015","journal-title":"J Hepatol"},{"key":"2025090800171591000_64.11.1824.63","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.10.001"},{"key":"2025090800171591000_64.11.1824.64","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27681"},{"key":"2025090800171591000_64.11.1824.65","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit226"},{"key":"2025090800171591000_64.11.1824.66","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu697"},{"issue":"(Suppl 2)","key":"2025090800171591000_64.11.1824.67","doi-asserted-by":"crossref","first-page":"S220","DOI":"10.1016\/S0168-8278(15)30071-4","article-title":"Long-term follow-up of treatment-emergent resistance-associated variants in NS3, NS5A and NS5B with Paritaprevir\/R-, Ombitasvir- and Dasabuvir-based regimens","volume":"62","author":"Krishnan","year":"2015","journal-title":"J Hepatol"},{"key":"2025090800171591000_64.11.1824.68","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27814"},{"issue":"(Suppl 2)","key":"2025090800171591000_64.11.1824.69","doi-asserted-by":"crossref","first-page":"S192","DOI":"10.1016\/S0168-8278(15)30012-X","article-title":"Retreatment of patients who failed 8 or 12 weeks of Ledipasvir\/Sofosbuvir-based regimens with Ledipasvir\/sofosbuvir for 24 weeks","volume":"62","author":"Lawitz","year":"2015","journal-title":"J Hepatol"},{"key":"2025090800171591000_64.11.1824.70","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27836"},{"key":"2025090800171591000_64.11.1824.71","first-page":"237","article-title":"Safety and efficacy of treatment with sofosbuvir+GS 5816 plus\/minus ribavirin for 8 or 12 weeks in treatment naive patients with genotype 1\u20136 HCV infection","volume":"60","author":"Tran","year":"2014","journal-title":"Hepatology"},{"issue":"Suppl 4","key":"2025090800171591000_64.11.1824.72","first-page":"297A","article-title":"High Efficacy of Treatment with Sofosbuvir+GS-5816 \u00b1Ribavirin for 12 Weeks in Treatment Experienced Patients with Genotype 1 or 3 HCV Infection","volume":"60","author":"Pianko","year":"2014","journal-title":"Hepatology"},{"key":"2025090800171591000_64.11.1824.73","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61228-9"},{"key":"2025090800171591000_64.11.1824.74","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61795-5"},{"key":"2025090800171591000_64.11.1824.75","first-page":"1281A","article-title":"Interim sustained virologic response (SVR) safety and tolerability results of 8 week treatment with ACH-3102 and sofosbuvir in chronic hepatitis C (HCV) genotype 1 treatment naive patients: a phase 2 \u201cproxy\u201d study","volume":"60","author":"Gane","year":"2014","journal-title":"Hepatology"},{"key":"2025090800171591000_64.11.1824.76","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27534"},{"key":"2025090800171591000_64.11.1824.77","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.3179"},{"key":"2025090800171591000_64.11.1824.78","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3010286"},{"key":"2025090800171591000_64.11.1824.79","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2013-306155"},{"key":"2025090800171591000_64.11.1824.80","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1405158"},{"key":"2025090800171591000_64.11.1824.81","doi-asserted-by":"publisher","DOI":"10.7326\/M14-1336"},{"key":"2025090800171591000_64.11.1824.82","doi-asserted-by":"publisher","DOI":"10.7326\/M14-1152"},{"key":"2025090800171591000_64.11.1824.83","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27736"},{"key":"2025090800171591000_64.11.1824.84","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.02.006"},{"key":"2025090800171591000_64.11.1824.85","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26141"},{"key":"2025090800171591000_64.11.1824.86","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12123"},{"key":"2025090800171591000_64.11.1824.87","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12172"},{"key":"2025090800171591000_64.11.1824.88","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu012"}],"container-title":["Gut"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/gutjnl-2015-310421","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T07:17:27Z","timestamp":1757315847000},"score":1,"resource":{"primary":{"URL":"https:\/\/gut.bmj.com\/lookup\/doi\/10.1136\/gutjnl-2015-310421"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,8]]},"references-count":88,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2015,10,8]]},"published-print":{"date-parts":[[2015,11]]}},"alternative-id":["10.1136\/gutjnl-2015-310421"],"URL":"https:\/\/doi.org\/10.1136\/gutjnl-2015-310421","relation":{},"ISSN":["0017-5749","1468-3288"],"issn-type":[{"value":"0017-5749","type":"print"},{"value":"1468-3288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,8]]}}}